China's epidemic has continued to heat up, and more places carry out larger all -member nucleic acid testing, but nucleic acid testing companies performing testing tasks report that it is difficult to obtain payment on time recently.
According to Bloomberg report on September 7, these testing service providers listed the growing scale of accounts receivable as one of their most concerned issues.One of the large nucleic acid testing providers and Hangzhou Dian Diagnostic Technology Group Co., Ltd. said that some unpaid accounts were canceled into bad debts.
This company, with the extension of the customer settlement cycle, large -scale testing is exhausted their financial resources.
The scale of accounts is rapidly expanding.According to calculations, as of June 30, the total accounts receivable of the eight large -scale virus testing agencies increased by 14.1 billion yuan (the same, about S $ 2.8 billion), a year -on -year increase of 73%.Among these companies, the largest increase is Lan Wei's medicine, reaching 189%.
Reporting pointed out that the delay of payment has highlighted the financial, economic and social costs brought by China's strict epidemic prevention strategy.With the increase of cases in various provinces, more and more China uses large -scale testing with the two -pronged approach of the city to prevent and control the epidemic.Even in cities without a city in Beijing and Shanghai, residents need to perform nucleic acid testing every three days in order to use public facilities or work.
Report analysis states that local governments responsible for undertaking large -scale detection costs are facing pressure.The decline in commercial activities has affected fiscal revenue, and expenditures related to epidemic are increasing.In addition to testing, these expenditures also include the construction of an isolated center and providing subsidies to the industry that has been hit hard.
"One possible reason is that in view of the subsequent accidents, the nucleic acid test budget at the beginning of the year may be underestimated," the Bloomberg industry studied a health industry analyst. "This may lead to reagent reagents.Producers' payment delays. "
In the latest financial report, the test service provider lists the growing amount of accounts receivable as one of their most concerned issues.
According to the first half of the performance report, Dian diagnosed the receivable of 10.7 billion yuan, which was higher than 5.4 billion yuan in the same period last year.risk".
Jinyu Medicine warned in the semi -annual report that the settlement cost settlement of nucleic acid testing in some areas may be postponed, and the epidemic may exacerbate some private medical institutions and clinics in poor operation, thereby bringing bad debt risk.
Runda Medical lists the growth of account receivables as one of the main risks facing the company.The company stated in its performance report that the settlement cycle of account receivables is prolonged, and the company is facing the possibility of further increasing the pressure on account receivable remittances.
This problem has spread to the investment market.Lanwei's stock price fell to the lowest level since March.According to its financial statements, the company's net cash flow of its operating activities is due to the long period of time for large screening nucleic acid testing business.Dian diagnosis has fallen 15%from the high in May.Goldland Medicine has received more than two years this week.
